Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Adjuvant-controlled Phase 1a/b Study on Safety and Tolerability With Ascending Multiple Doses of IMX101 in H. Pylori-negative and H. Pylori-infected Healthy Volunteers

NCT03270800 is registered in ClinicalTrials.gov with ImevaX as lead sponsor.

NCT NCT03270800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03270800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Adjuvant-controlled Phase 1a/b Study on Safety and Tolerability With Ascending Multiple Doses of IMX101 in H. Pylori-negative and H. Pylori-infected Healthy Volunteers
Lead sponsor
ImevaX
Phase
Phase 1
Overall status
Completed
Start date
January 30, 2017
Completion date
December 23, 2018
Enrollment
72 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

helicobacter pylori infected subjects, helicobacter pylori naive subjects